Suppr超能文献

内皮钙激活钾通道的药理学激活剂可增加麻醉猪模型的全身电导并降低动脉血压。

A pharmacologic activator of endothelial KCa channels increases systemic conductance and reduces arterial pressure in an anesthetized pig model.

作者信息

Mishra Ramesh C, Mitchell Jamie R, Gibbons-Kroeker Carol, Wulff Heike, Belenkie Israel, Tyberg John V, Braun Andrew P

机构信息

Dept. of Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; The Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada.

Dept of Physiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

出版信息

Vascul Pharmacol. 2016 Apr;79:24-31. doi: 10.1016/j.vph.2015.07.016. Epub 2015 Aug 1.

Abstract

SKA-31, an activator of endothelial KCa2.3 and KCa3.1 channels, reduces systemic blood pressure in mice and dogs, however, its effects in larger mammals are not well known. We therefore examined the hemodynamic effects of SKA-31, along with sodium nitroprusside (SNP), in anesthetized, juvenile male domestic pigs. Experimentally, continuous measurements of left ventricular (LV), aortic and inferior vena cava (IVC) pressures, along with flows in the ascending aorta, carotid artery, left anterior descending coronary artery and renal artery, were performed during acute administration of SKA-31 (0.1, 0.3, 1.0, 3.0 and 5.0mg/ml/kg) and a single dose of SNP (5.0 μg/ml/kg). SKA-31 dose-dependently reduced mean aortic pressure (mPAO), with the highest dose decreasing mPAO to a similar extent as SNP (-23 ± 3 and -28 ± 4 mmHg, respectively). IVC pressure did not change. Systemic conductance and conductance in coronary and carotid arteries increased in response to SKA-31 and SNP, but renal artery conductance was unaffected. There was no change in either LV stroke volume (SV) or heart rate (versus the preceding control) for any infusion. With no change in SV, drug-evoked decreases in LV stroke work (SW) were attributed to reductions in mPAO (SW vs. mPAO, r(2)=0.82, P<0.001). In summary, SKA-31 dose-dependently reduced mPAO by increasing systemic and arterial conductances. Primary reductions in mPAO by SKA-31 largely account for associated decreases in SW, implying that SKA-31 does not directly impair cardiac contractility.

摘要

SKA - 31是一种内皮钙激活钾通道KCa2.3和KCa3.1的激活剂,可降低小鼠和犬的全身血压,然而,其在较大哺乳动物中的作用尚不清楚。因此,我们研究了SKA - 31与硝普钠(SNP)在麻醉的幼年雄性家猪中的血流动力学效应。实验中,在急性给予SKA - 31(0.1、0.3、1.0、3.0和5.0mg/ml/kg)和单剂量SNP(5.0μg/ml/kg)期间,连续测量左心室(LV)、主动脉和下腔静脉(IVC)压力,以及升主动脉、颈动脉、左前降支冠状动脉和肾动脉中的血流。SKA - 31剂量依赖性地降低平均主动脉压(mPAO),最高剂量降低mPAO的程度与SNP相似(分别为-23±3和-28±4mmHg)。IVC压力未改变。SKA - 31和SNP使全身电导以及冠状动脉和颈动脉的电导增加,但肾动脉电导未受影响。任何输注情况下,LV每搏输出量(SV)或心率(相对于先前对照)均无变化。由于SV无变化,药物引起的LV每搏功(SW)降低归因于mPAO的降低(SW与mPAO,r(2)=0.82,P<0.001)。总之,SKA - 31通过增加全身和动脉电导来剂量依赖性地降低mPAO。SKA - 31对mPAO的原发性降低在很大程度上解释了SW的相关降低,这意味着SKA - 31不会直接损害心脏收缩力。

相似文献

2
SKA-31, an activator of endothelial Ca-activated K channels evokes robust vasodilation in rat mesenteric arteries.
Eur J Pharmacol. 2018 Jul 15;831:60-67. doi: 10.1016/j.ejphar.2018.05.006. Epub 2018 May 9.
9
New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1.
Mol Pharmacol. 2014 Sep;86(3):342-57. doi: 10.1124/mol.114.093286. Epub 2014 Jun 23.

引用本文的文献

1
Endothelial KCa channels: Novel targets to reduce atherosclerosis-driven vascular dysfunction.
Front Pharmacol. 2023 Mar 31;14:1151244. doi: 10.3389/fphar.2023.1151244. eCollection 2023.
3
Hydrophobic interactions between the HA helix and S4-S5 linker modulate apparent Ca sensitivity of SK2 channels.
Acta Physiol (Oxf). 2021 Jan;231(1):e13552. doi: 10.1111/apha.13552. Epub 2020 Sep 10.
4
SKA-31, an activator of Ca-activated K channels, improves cardiovascular function in aging.
Pharmacol Res. 2020 Jan;151:104539. doi: 10.1016/j.phrs.2019.104539. Epub 2019 Nov 7.
6
Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels.
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:219-240. doi: 10.1146/annurev-pharmtox-010919-023420. Epub 2019 Jul 23.
8
Pharmacologic targeting of endothelial Ca-activated K channels: A strategy to improve cardiovascular function.
Channels (Austin). 2018 Jan 1;12(1):126-136. doi: 10.1080/19336950.2018.1454814.
9
Protective role of ACE2-Ang-(1-7)-Mas in myocardial fibrosis by downregulating K3.1 channel via ERK1/2 pathway.
Pflugers Arch. 2016 Nov;468(11-12):2041-2051. doi: 10.1007/s00424-016-1875-9. Epub 2016 Sep 3.
10
Vascular Reactivity Profile of Novel KCa 3.1-Selective Positive-Gating Modulators in the Coronary Vascular Bed.
Basic Clin Pharmacol Toxicol. 2016 Aug;119(2):184-92. doi: 10.1111/bcpt.12560. Epub 2016 Feb 29.

本文引用的文献

3
Selective phosphorylation modulates the PIP2 sensitivity of the CaM-SK channel complex.
Nat Chem Biol. 2014 Sep;10(9):753-9. doi: 10.1038/nchembio.1592. Epub 2014 Aug 10.
4
A pharmacologic activator of endothelial KCa channels enhances coronary flow in the hearts of type 2 diabetic rats.
J Mol Cell Cardiol. 2014 Jul;72:364-73. doi: 10.1016/j.yjmcc.2014.04.013. Epub 2014 Apr 29.
6
Heterogeneous upregulation of apamin-sensitive potassium currents in failing human ventricles.
J Am Heart Assoc. 2013 Jan 3;2(1):e004713. doi: 10.1161/JAHA.112.004713.
8
SKA-31, a novel activator of SK(Ca) and IK(Ca) channels, increases coronary flow in male and female rat hearts.
Cardiovasc Res. 2013 Feb 1;97(2):339-48. doi: 10.1093/cvr/cvs326. Epub 2012 Oct 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验